engleski

Sodium-glucose cotransporter Sglt1 (Slc5a1) is present in various murine organs with sex-related expression in kidneys

Novel antidiabetic drugs have been developed aimed to lower blood glucose by inhibiting sodium-D-glucose cotransporter 1 (Sglt1) in intestine and kidneys. In mice, the intestinal Sglt1, localized in the enterocyte brush-border membrane (BBM), is responsible for bulk (>80%) glucose absorption, whereas the transporter in the BBM of renal proximal tubules (PT) contributes to ~3% glucose reabsorption. The presence of Sglt1 in other mammalian organs, which could represent possible targets of novel inhibitors, is poorly known. Here we compared the expression of Sglt1 mRNA and its protein in various organs of wild type (WT) and Sglt1 knockout (KO) mice by quantitative RT-PCR and immunocytochemistry (IC). In WT, but not in KO mice, the Sglt1 mRNA expression was highest in small intestine ; high in seminal vesicles, kidneys and salivary glands ; medium in prostate, tongue, eyes and uterus, and small in pancreas, lungs and liver. By IC in WT mice, Sglt1 protein was detected in small intestine (enterocytes, BBM), kidneys (PT, BBM ; thick ascending limbs, luminal membrane (LM)), eyes (optical nerves), liver (bile ducts, LM), pancreas (ducts, LM), salivary glands (serous acini and initial ducts, LM), tongue (taste epithelium, plasma membrane), prostate (myoepithelial cells), bulbourethral gland (duct cells, LM), seminal vesicles (myoepithelial cells), and uterus (endometrial cells, LM). In kidneys, we observed sex-dependent expression of Sglt1 mRNA (females>males) and its protein (males>females) indicating different transcriptional and post-translational regulations. Diverse localizations of Sglt1 in various organs may represent targets of novel inhibitors with unpredictable health consequences in diabetic patients. Funded by Croatian Science Foundation-project#1481.

qRT-PCR ; antidiabetic drugs ; immunocytochemistry

nije evidentirano